BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBIO BridgeBio Pharma, Inc.

盘后交易 04-16 16:47:42 EDT

25.24

-0.53

-2.06%

盘后25.18

-0.06-0.24%

16:34 EDT

最高25.91	最低25.20	成交量103.84万
今开25.39	昨收25.77	日振幅2.76%
总市值46.56亿	流通市值29.93亿	总股本1.84亿
成交额2,640万	换手率0.88%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBIO","market":"US","secType":"STK","nameCN":"BridgeBio Pharma, Inc.","latestPrice":25.24,"timestamp":1713297600000,"preClose":25.77,"halted":0,"volume":1038441,"hourTrading":{"tag":"盘后","latestPrice":25.18,"preClose":25.24,"latestTime":"16:34 EDT","volume":58664,"amount":1480681.002592,"timestamp":1713299680694},"delay":0,"floatShares":118565337,"shares":184452226,"eps":-3.951078,"marketStatus":"盘后交易","marketStatusCode":4,"change":-0.53,"latestTime":"04-16 16:47:42 EDT","open":25.39,"high":25.91,"low":25.2,"amount":26395976.012849998,"amplitude":0.027551,"askPrice":26.45,"askSize":100,"bidPrice":25.15,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-3.951078,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1713312000000},"adr":0,"listingDate":1561608000000,"adjPreClose":25.77,"preHourTrading":{"tag":"盘前","latestPrice":25.18,"preClose":25.77,"latestTime":"08:06 EDT","volume":127,"amount":3211.779962,"timestamp":1713269218667},"postHourTrading":{"tag":"盘后","latestPrice":25.18,"preClose":25.24,"latestTime":"16:34 EDT","volume":58664,"amount":1480681.002592,"timestamp":1713299680694},"volumeRatio":0.648279},"requestUrl":"/m/hq/s/BBIO?invite=033TIGER","defaultTab":"news","newsList":[{"id":"2426734287","title":"Bridgebio Pharma, Inc.盘中异动 临近午盘快速跳水5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426734287","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426734287?lang=zh_cn&edition=full","pubTime":"2024-04-12 23:43","pubTimestamp":1712936581,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日23时43分，Bridgebio Pharma, Inc.股票出现波动，股价快速跳水5.01%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.89%。其相关个股中，Paxmedica, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Allarity Therapeutics, Inc.涨幅较大，Allarity Therapeutics, Inc.、Paxmedica, Inc.、Aptevo Therapeutics Inc.较为活跃，换手率分别为3399.94%、1343.08%、82.63%，振幅较大的相关个股有Paxmedica, Inc.、Allarity Therapeutics, Inc.、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为90.30%、60.95%、58.59%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041223430279203ed2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041223430279203ed2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426299354","title":"Bridgebio Pharma, Inc.盘中异动 下午盘急速上涨5.01%报28.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426299354","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426299354?lang=zh_cn&edition=full","pubTime":"2024-04-12 02:17","pubTimestamp":1712859445,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日02时17分，Bridgebio Pharma, Inc.股票出现异动，股价快速拉升5.01%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，Rallybio Corporation、Eliem Therapeutics, Inc、Candel Therapeutics, Inc.涨幅较大，Adial Pharmaceuticals, Inc、Aptevo Therapeutics Inc.、Scisparc Ltd.较为活跃，换手率分别为812.12%、614.74%、516.20%，振幅较大的相关个股有Veru Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Rallybio Corporation，振幅分别为53.23%、52.42%、50.92%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041202172587e7faef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041202172587e7faef&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426487254","title":"Bridgebio Pharma, Inc.盘中异动 下午盘大幅下跌5.08%报26.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426487254","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426487254?lang=zh_cn&edition=full","pubTime":"2024-04-11 01:07","pubTimestamp":1712768847,"startTime":"0","endTime":"0","summary":"北京时间2024年04月11日01时07分，Bridgebio Pharma, Inc.股票出现波动，股价急速跳水5.08%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为1.23%。其相关个股中，Adial Pharmaceuticals, Inc、Jaguar Health, Inc.、Clene Inc C/Wts 30/12/2025 涨幅较大，Adial Pharmaceuticals, Inc、Silo Pharma, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为1946.31%、76.78%、53.12%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Orgenesis Inc.、Nutriband Inc C/Wts ，振幅分别为87.61%、74.23%、52.44%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110107287a51ed76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110107287a51ed76&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420798966","title":"美国研究综述-迪克体育用品、Nvidia、PVH","url":"https://stock-news.laohu8.com/highlight/detail?id=2420798966","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420798966?lang=zh_cn&edition=full","pubTime":"2024-03-20 15:14","pubTimestamp":1710918896,"startTime":"0","endTime":"0","summary":"    路透社3月20日 - 华尔街证券分析师周三调整了对迪克体育用品公司、英伟达和 PVH 等几家美国上市公司的评级和目标价。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417781874","title":"美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2417781874","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417781874?lang=zh_cn&edition=full","pubTime":"2024-03-07 14:49","pubTimestamp":1709794169,"startTime":"0","endTime":"0","summary":"    路透社3月7日 - 华尔街证券分析师周四修改了对几家美国上市公司的评级和目标价，其中包括 Highpeak Energy、Nordstrom 和 Victoria'S Secret & Co。公司要闻             * Highpeak Energy Inc   ：Gerdes Energy Research将其评级从买入下调至卖出             * Nordstrom Inc   ：杰富瑞将其评级从买入下调至持有             * 维多利亚的秘密   ：摩根大通将其股票评级从 \"中性 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417414969","title":"Bridgebio Pharma, Inc.盘中异动 急速跳水5.02%报30.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417414969","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417414969?lang=zh_cn&edition=full","pubTime":"2024-03-05 22:34","pubTimestamp":1709649261,"startTime":"0","endTime":"0","summary":"北京时间2024年03月05日22时34分，Bridgebio Pharma, Inc.股票出现波动，股价大幅下跌5.02%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.28%。其相关个股中，Apogee Therapeutics, Inc.、Jasper Therapeutics Inc C/Wts 24/09/2026 、Ys Biopharma Co Ltd C/Wts 15/03/2028 涨幅较大，Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.、CASI制药较为活跃，换手率分别为205.47%、92.43%、45.68%，振幅较大的相关个股有Ocean Biomedical Inc C/Wts 14/02/2028 、Ocean Biomedical, Inc.、Eyenovia, Inc.，振幅分别为25.10%、17.89%、17.54%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030522342287e76184&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030522342287e76184&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417176870","title":"美国研究综述-CommScope Holding Company、Dutch Bros、Hess","url":"https://stock-news.laohu8.com/highlight/detail?id=2417176870","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417176870?lang=zh_cn&edition=full","pubTime":"2024-03-05 03:21","pubTimestamp":1709580103,"startTime":"0","endTime":"0","summary":"    路透社3月4日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 CommScope Holding Company、Dutch Bros 和 Hess。要点 * CommScope Holding Company   ：摩根大通将其股票评级从中性下调至减持  * 荷兰兄弟  ：Piper Sandler 将其评级从中性上调至增持  * Hess Corp   ：Susquehanna 将目标价从 152 美元上调至 156 美元  * Pioneer Natural Resources Co   ：苏斯克汉纳将目标价从237美元上调至246美元  * United Therapeutics Corp   ：摩根大通将目标价从294美元下调至280美元  以下是路透社周一报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416142992","title":"Bridgebio Pharma, Inc.盘中异动 早盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416142992","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416142992?lang=zh_cn&edition=full","pubTime":"2024-03-04 22:43","pubTimestamp":1709563437,"startTime":"0","endTime":"0","summary":"北京时间2024年03月04日22时43分，Bridgebio Pharma, Inc.股票出现异动，股价急速跳水5.05%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为0.51%。其相关个股中，Quoin Pharmaceuticals Ltd、Tc Biopharm  Plc C/Wts 10/02/2028 、Jaguar Health, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为1392.03%、192.88%、75.53%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.，振幅分别为63.43%、50.90%、27.12%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030422435787e75ae8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030422435787e75ae8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416114115","title":"BUZZ-BridgeBio 因与拜耳达成心脏病药物许可协议而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2416114115","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2416114115?lang=zh_cn&edition=full","pubTime":"2024-03-04 20:11","pubTimestamp":1709554311,"startTime":"0","endTime":"0","summary":"    3月4日 - ** BridgeBio Pharma   股价盘前上涨1%至36.0美元** 该公司表示， ，它已与德国制药商拜耳  达成了在欧洲商业化其心脏病药物的许可协议** 该药名为acoramidis，是一种治疗转甲状腺素淀粉样变性心肌病的口服药物。** 根据交易，BBIO 将获得高达 3.1 亿美元的收益，包括前期和里程碑付款 - BBIO** Says 还将获得分级版税，从阿可拉米地斯在欧洲销售额的 30% 开始 -BBIO** TD COwen 分析师 Tyler Van Buren 在一份说明中写道：\"这是一笔可靠的交易，而且鉴于年底前可能获得批准，时机非常合适。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416199737","title":"拜耳(BAYRY.US)获得BridgeBio(BBIO.US)心脏病药物欧洲独家商业权","url":"https://stock-news.laohu8.com/highlight/detail?id=2416199737","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2416199737?lang=zh_cn&edition=full","pubTime":"2024-03-04 17:05","pubTimestamp":1709543141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BridgeBio Pharma授予德国制药商拜耳在欧洲商业化其心脏病药物acoramidis的独家许可。BridgeBio将获得高达3.1亿美元的资金，包括前期和近期里程碑付款，以及其他未披露的销售里程碑付款。BridgeBio还将获得acoramidis在欧洲销售的分层版税。美国卫生监管机构已将acoramidis的批准决定日期定为11月29日，而该药物有望在2025年获得欧盟批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1080978.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2416642526","title":"Bridgebio Pharma, Inc.盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416642526","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416642526?lang=zh_cn&edition=full","pubTime":"2024-03-01 23:15","pubTimestamp":1709306105,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日23时15分，Bridgebio Pharma, Inc.股票出现异动，股价急速拉升5.04%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体涨幅为1.69%。其相关个股中，Biovie Inc.、Adial Pharmaceuticals, Inc、Carmell Corp C/Wts 12/07/2028 涨幅较大，Adial Pharmaceuticals, Inc、Enveric Biosciences, Inc.、Biovie Inc.较为活跃，换手率分别为2851.85%、310.89%、134.26%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Carmell Corp C/Wts 12/07/2028 、Biovie Inc.，振幅分别为81.48%、71.25%、69.35%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240301231506861da942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240301231506861da942&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414802039","title":"Bridgebio Pharma Inc盘中异动 临近午盘股价大涨5.12%报36.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2414802039","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414802039?lang=zh_cn&edition=full","pubTime":"2024-02-28 00:32","pubTimestamp":1709051551,"startTime":"0","endTime":"0","summary":"北京时间2024年02月28日00时32分，Bridgebio Pharma Inc股票出现异动，股价急速拉升5.12%。截至发稿，该股报36.66美元/股，成交量28.7202万股，换手率0.16%，振幅4.27%。Bridgebio Pharma Inc股票所在的生物技术行业中，整体跌幅为0.12%。Bridgebio Pharma Inc公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022800323187e73a5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022800323187e73a5d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413825204","title":"BridgeBio Pharma Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2413825204","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413825204?lang=zh_cn&edition=full","pubTime":"2024-02-23 11:02","pubTimestamp":1708657325,"startTime":"0","endTime":"0","summary":"   * BridgeBio Pharma Inc   报告了截至12月底的季度调整后每股亏损96美分，低于去年同期的每股收益-92美分。华尔街预期为每股亏损 1.16 美元至-72 美分。* 营收同比下降 6.7% 至 175 万美元，分析师预期为 623 万美元。* BridgeBio Pharma 公司公布的本季度每股收益为亏损 96 美分。* 该公司当季亏损 1.6815 亿美元。* BridgeBio Pharma Inc 本季度股价下跌了 15.4%。2月23日 - 预测变化   * 在过去三个月中，分析师的平均盈利预测上升了约 1.1%。华尔街对 BridgeBio Pharma Inc 的 12 个月目标价中位数为 50.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413648394","title":"Bridgebio Pharma Inc盘中异动 股价大跌5.21%报35.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413648394","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413648394?lang=zh_cn&edition=full","pubTime":"2024-02-21 01:37","pubTimestamp":1708450635,"startTime":"0","endTime":"0","summary":"北京时间2024年02月21日01时37分，Bridgebio Pharma Inc股票出现波动，股价大幅下挫5.21%。Bridgebio Pharma Inc股票所在的生物技术行业中，整体跌幅为0.90%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Monopar Therapeutics Inc涨幅较大，Scisparc Ltd、Monopar Therapeutics Inc、Clearmind Medicine Inc较为活跃，换手率分别为2552.97%、602.29%、343.49%，振幅较大的相关个股有Sab Biotherapeutics Inc C/Wts 22/10/2026 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Monopar Therapeutics Inc，振幅分别为1060.57%、333.33%、233.51%。Bridgebio Pharma Inc公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402210137157912cbec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402210137157912cbec&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2412131154","title":"BridgeBio Pharma Inc   预计每股亏损 91 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2412131154","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412131154?lang=zh_cn&edition=full","pubTime":"2024-02-19 22:50","pubTimestamp":1708354224,"startTime":"0","endTime":"0","summary":"   * BridgeBio Pharma Inc    预计将在2月21日公布截至2023年12月31日的季度业绩(预计)，季度收入将有所增长。* LSEG 分析师对 BridgeBio Pharma Inc 的平均预期是每股亏损 91 美分。* 目前，分析师对该公司股票的平均评级为 \"买入\"，建议分类为11个 \"强烈买入 \"或 \"买入\"，2个 \"持有\"，没有 \"卖出 \"或 \"强烈卖出\"。* 华尔街对 BridgeBio Pharma Inc 的 12 个月目标价中位数为 50.00 美元，高于其上次收盘价 37.21 美元。2月19日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412696674","title":"Bridgebio Pharma Inc盘中异动 急速跳水5.02%报37.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2412696674","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2412696674?lang=zh_cn&edition=full","pubTime":"2024-02-17 01:58","pubTimestamp":1708106302,"startTime":"0","endTime":"0","summary":"北京时间2024年02月17日01时58分，Bridgebio Pharma Inc股票出现异动，股价大幅跳水5.02%。Bridgebio Pharma Inc公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。消息层面，截至01时58分，Bridgebio Pharma Inc股票正面舆情新闻比例50%。《BridgeBio Pharma董事增持3,433股普通股股份，价值约4.45万美元》资讯为影响Bridgebio Pharma Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217015822861d5938&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217015822861d5938&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411252722","title":"BUZZ-竞争对手 Alnylam 更改心脏病药物研究目标后，BridgeBio 公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2411252722","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411252722?lang=zh_cn&edition=full","pubTime":"2024-02-16 03:34","pubTimestamp":1708025681,"startTime":"0","endTime":"0","summary":"    2月15日 - ** 制药商Bridgebio Pharma   股价上涨19.4%，至41.01美元 ** 如果涨势得以保持，股价将创7个多月来最大单日涨幅 ** Alnylam   修改了  关键目标，以测试其药物Amvuttra作为ATTR淀粉样变性相关心肌病的治疗方法。** BBIO正在开发一种名为acoramidis的药物，用于治疗同一种疾病，目前正处于后期试验阶段。** 瑞穗证券公司表示：\"除非公司觉得有必要，否则不会随便改变统计计划。** 股价在过去 12 个月中增长了两倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411554906","title":"Bridgebio Pharma Inc股价拉升10.33% 市值涨6.81亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411554906","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411554906?lang=zh_cn&edition=full","pubTime":"2024-02-15 22:32","pubTimestamp":1708007541,"startTime":"0","endTime":"0","summary":"北京时间2024年02月15日22时32分，Bridgebio Pharma Inc股票出现异动，股价急速拉升10.33%。Bridgebio Pharma Inc股票所在的生物技术行业中，整体跌幅为0.06%。Bridgebio Pharma Inc公司简介：BridgeBio Pharma Inc 参与确定用于治疗孟德尔病患者的先进变革性药物，以及具有明确基因驱动因素的癌症。消息层面，截至22时32分，Bridgebio Pharma Inc股票正面舆情新闻比例50%。《BridgeBio Pharma董事增持3,433股普通股股份，价值约4.45万美元》资讯为影响Bridgebio Pharma Inc的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215223221818f71f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240215223221818f71f5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2411658886","title":"KKR 收购健康科技公司 Cotiviti 的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2411658886","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411658886?lang=zh_cn&edition=full","pubTime":"2024-02-14 23:16","pubTimestamp":1707923787,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社2月14日 - 私募股权公司KKR & Co   周三表示，已同意从私募股权管理公司Veritas Capital手中收购Cotiviti的股份。熟悉内情的消息人士周三早些时候告诉路透社，KKR是收购Cotiviti 50%股份的主要竞争者，交易价值将在100亿到110亿美元之间 (link)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bridgebio.com","stockEarnings":[{"period":"1week","weight":-0.0884},{"period":"1month","weight":-0.0649},{"period":"3month","weight":-0.3143},{"period":"6month","weight":-0.0119},{"period":"1year","weight":0.7483},{"period":"ytd","weight":-0.3617}],"compareEarnings":[{"period":"1week","weight":-0.0275},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0622},{"period":"6month","weight":0.1726},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.0613}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Pharma, Inc.于2019年5月17日成立为特拉华州公司。他们是一个由经验丰富的药物发现者，开发者和创新者组成的团队，致力于创造改变生命的药物，从源头上瞄准特征明确的遗传性疾病。他们确定和推进转化药物治疗患有孟德尔疾病的患者，这些疾病是由单一基因缺陷引起的疾病，以及具有明确遗传驱动因素的癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.111762},{"month":2,"riseRate":0.4,"avgChangeRate":0.037273},{"month":3,"riseRate":0.4,"avgChangeRate":0.087947},{"month":4,"riseRate":0.2,"avgChangeRate":-0.108021},{"month":5,"riseRate":0.25,"avgChangeRate":-0.046032},{"month":6,"riseRate":1,"avgChangeRate":0.181159},{"month":7,"riseRate":0.4,"avgChangeRate":0.163437},{"month":8,"riseRate":0.6,"avgChangeRate":0.020787},{"month":9,"riseRate":0.2,"avgChangeRate":-0.055084},{"month":10,"riseRate":0.8,"avgChangeRate":0.03327},{"month":11,"riseRate":0.6,"avgChangeRate":0.082541},{"month":12,"riseRate":0.6,"avgChangeRate":0.051049}],"exchange":"NASDAQ","name":"BridgeBio Pharma, Inc.","nameEN":"BridgeBio Pharma, Inc."},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Pharma, Inc.,BBIO,BridgeBio Pharma, Inc.股票,BridgeBio Pharma, Inc.股票老虎,BridgeBio Pharma, Inc.股票老虎国际,BridgeBio Pharma, Inc.行情,BridgeBio Pharma, Inc.股票行情,BridgeBio Pharma, Inc.股价,BridgeBio Pharma, Inc.股市,BridgeBio Pharma, Inc.股票价格,BridgeBio Pharma, Inc.股票交易,BridgeBio Pharma, Inc.股票购买,BridgeBio Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}